Role of SHE and ABL signaling in vascular tubulogenesis
SHE 和 ABL 信号在血管生成中的作用
基本信息
- 批准号:10587279
- 负责人:
- 金额:$ 63.94万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-03-01 至 2026-11-30
- 项目状态:未结题
- 来源:
- 关键词:Adaptor Signaling ProteinAdhesionsAortaBiochemicalBiological AssayBiological ProcessBiomedical EngineeringBlood VesselsCell Culture TechniquesCell SeparationCellsChemicalsClinicalCytoskeletal ModelingCytoskeletonDataDefectDevelopmentDiameterDiseaseDorsalE proteinEmbryoEndothelial CellsEventFamilyGeneticGrowthHumanKnowledge acquisitionLesionMaintenanceModelingMolecularMorphogenesisMusNatural regenerationOrganismPathologicPatientsPhosphotransferasesPlayProcessProtein Tyrosine KinaseProteinsRoleSignal PathwaySignal TransductionTestingTherapeuticTubeVascular DiseasesVascular Endothelial CellVascular EndotheliumVenous MalformationXenograft ModelXenograft procedureZebrafishcell motilitycell typeexperimental studyfluid flowhuman diseaseimprovedinhibitormalformationmutantnovelnovel strategiesnovel therapeutic interventionoverexpressionregenerative therapyrepairedrho GTP-Binding Proteinsthree dimensional cell culturetoolvascular bed
项目摘要
Project Summary
Formation of vascular lumen of appropriate size, or tubulogenesis, is one of critical steps during
vascular development. Many vascular diseases including venous malformations are associated with malformed
or enlarged lumens. However, we still have a limited understanding of molecular events that regulate vascular
lumen size.
Abelson (Abl) kinase signaling regulates diverse processes during development and disease, including
cytoskeletal reorganization required for cell morphogenesis, cell motility, adhesion and polarity. Abl signaling in
different cell types can induce activation of Rho GTPases, which are known key regulators of lumen formation.
However, the role of Abl signaling in regulating vascular lumen size has not been previously investigated.
Src homology 2 domain containing E (She) protein was originally identified as a highly conserved
factor, which interacted with Abl kinase. We have previously demonstrated that She is specifically expressed in
embryonic vasculature in zebrafish embryos. However, its biological function is still unknown in any organism.
Here we obtained preliminary data which argues that She acts as a novel regulator of vascular lumen
size. Zebrafish mutant embryos deficient in she function display enlarged vascular lumen within the dorsal
aorta. Similarly, human vascular endothelial cells, deficient in SHE function, form enlarged tubes. Our
preliminary data further suggest that She functions as a novel regulator of Abl signaling, and argue that ABL
signaling and lumen formation are misregulated in human venous malformation (VM), suggesting a potential
role for ABL and SHE in human disease. We hypothesize that SHE is a novel adaptor protein which functions
in the ABL kinase signaling pathway to restrict lumen size during vascular tubulogenesis. We further
hypothesize that SHE overexpression may reduce lumen size in VM leading to a novel therapeutic approach.
The following specific aims are proposed: 1) Determine the cellular and molecular mechanisms by
which She regulates tubulogenesis; 2) Determine if She restricts lumen size by inhibiting Abl kinase signaling
pathway; 3) Determine if She overexpression can reduce lumen size in VM. Zebrafish embryos deficient in
she function will be analyzed for cellular and molecular defects in vascular tubulogenesis. Conservation of She
function will be tested in human vascular endothelial cells. The role of Abl kinase signaling in tubulogenesis
and its interaction with She will be analyzed using chemical inhibitors, genetic mutants and biochemical assays
in zebrafish embryos and human cells. The therapeutic potential of SHE to reduce the size of vascular lumen
will be analyzed in the cell culture and mouse VM model as well as in primary cells isolated from VM patients.
Obtained results will identify the role for SHE and ABL signaling during normal and pathological tubulogenesis,
which may lead to the development of novel strategies to treat vascular malformations.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Saulius Sumanas其他文献
Saulius Sumanas的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Saulius Sumanas', 18)}}的其他基金
The role of Collagen COL22A1 in intracranial aneurysms and vascular stability
胶原蛋白 COL22A1 在颅内动脉瘤和血管稳定性中的作用
- 批准号:
9926909 - 财政年份:2017
- 资助金额:
$ 63.94万 - 项目类别:
The role of Collagen COL22A1 in intracranial aneurysms and vascular stability
胶原蛋白 COL22A1 在颅内动脉瘤和血管稳定性中的作用
- 批准号:
9381376 - 财政年份:2017
- 资助金额:
$ 63.94万 - 项目类别:
THE ROLE OF COLLAGEN COL22A1 IN INTRACRANIAL ANEURYSMS AND VASCULAR STABILITY
胶原蛋白 COL22A1 在颅内动脉瘤和血管稳定性中的作用
- 批准号:
10212566 - 财政年份:2017
- 资助金额:
$ 63.94万 - 项目类别:
Molecular Mechanisms of Arterial-Venous Differentiation in Zebrafish
斑马鱼动静脉分化的分子机制
- 批准号:
8083384 - 财政年份:2011
- 资助金额:
$ 63.94万 - 项目类别:
Molecular Mechanisms of Arterial-Venous Differentiation
动静脉分化的分子机制
- 批准号:
8645705 - 财政年份:2011
- 资助金额:
$ 63.94万 - 项目类别:
Molecular Mechanisms of Arterial-Venous Differentiation
动静脉分化的分子机制
- 批准号:
8449174 - 财政年份:2011
- 资助金额:
$ 63.94万 - 项目类别:
Molecular Mechanisms of Arterial-Venous Differentiation
动静脉分化的分子机制
- 批准号:
8827404 - 财政年份:2011
- 资助金额:
$ 63.94万 - 项目类别:
相似海外基金
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y004841/1 - 财政年份:2024
- 资助金额:
$ 63.94万 - 项目类别:
Research Grant
Defining a role for non-canonical mTORC1 activity at focal adhesions
定义非典型 mTORC1 活性在粘着斑中的作用
- 批准号:
BB/Y001427/1 - 财政年份:2024
- 资助金额:
$ 63.94万 - 项目类别:
Research Grant
How tensins transform focal adhesions into fibrillar adhesions and phase separate to form new adhesion signalling hubs.
张力蛋白如何将粘着斑转化为纤维状粘连并相分离以形成新的粘连信号中枢。
- 批准号:
BB/Y005414/1 - 财政年份:2024
- 资助金额:
$ 63.94万 - 项目类别:
Research Grant
Development of a single-use, ready-to-use, sterile, dual chamber, dual syringe sprayable hydrogel to prevent postsurgical cardiac adhesions.
开发一次性、即用型、无菌、双室、双注射器可喷雾水凝胶,以防止术后心脏粘连。
- 批准号:
10669829 - 财政年份:2023
- 资助金额:
$ 63.94万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 63.94万 - 项目类别:
Improving Maternal Outcomes of Cesarean Delivery with the Prevention of Postoperative Adhesions
通过预防术后粘连改善剖宫产的产妇结局
- 批准号:
10821599 - 财政年份:2023
- 资助金额:
$ 63.94万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10841832 - 财政年份:2023
- 资助金额:
$ 63.94万 - 项目类别:
Prevention of Intraabdominal Adhesions via Release of Novel Anti-Inflammatory from Surface Eroding Polymer Solid Barrier
通过从表面侵蚀聚合物固体屏障中释放新型抗炎剂来预防腹内粘连
- 批准号:
10532480 - 财政年份:2022
- 资助金额:
$ 63.94万 - 项目类别:
I-Corps: A Sprayable Tissue-Binding Hydrogel to Prevent Postsurgical Cardiac Adhesions
I-Corps:一种可喷雾的组织结合水凝胶,可防止术后心脏粘连
- 批准号:
10741261 - 财政年份:2022
- 资助金额:
$ 63.94万 - 项目类别:
Sprayable Polymer Blends for Prevention of Site Specific Surgical Adhesions
用于预防特定部位手术粘连的可喷涂聚合物共混物
- 批准号:
10674894 - 财政年份:2022
- 资助金额:
$ 63.94万 - 项目类别: